Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PAVmed (PAVM) EBITDA Margin (2021 - 2025)

PAVmed has reported EBITDA Margin over the past 5 years, most recently at 8398.77% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4347123.0% year-over-year to 8398.77%; the TTM value through Dec 2025 reached 21808.0%, down 2019087.0%, while the annual FY2025 figure was 21806.0%, 2032062.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 8398.77% at PAVmed, up from 96880.0% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 1389.7% in Q1 2024 and troughed at 96880.0% in Q3 2025.
  • A 5-year average of 25069.85% and a median of 9164.44% in 2023 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 4347123bps in 2025 and fell as far as -7718558bps in 2025.
  • Year by year, EBITDA Margin stood at 6559.67% in 2021, then plummeted by -235bps to 21965.18% in 2022, then skyrocketed by 93bps to 1561.77% in 2023, then crashed by -3221bps to 51870.0% in 2024, then soared by 84bps to 8398.77% in 2025.
  • Business Quant data shows EBITDA Margin for PAVM at 8398.77% in Q4 2025, 96880.0% in Q3 2025, and 78583.33% in Q2 2025.